Praxis Precision Medicines has reported topline data from the Phase IIb Essential1 trial of ulixacaltamide (PRAX-944) to treat essential tremor (ET). The placebo-controlled, randomised, dose range finding, double-blind trial has been designed for assessing the safety, tolerability, and efficacy of once-a-day 60mg or 100mg ulixacaltamide treatment against a placebo after 56 days.
IRVINE, Calif., March 15, 2022 /PRNewswire/ — Allevion Therapeutics announced today that the Medical and Scientific Advisory Board (SAB) is expanding to include three new members — Rajesh Pahwa, M.D., Stuart H. Isaacson, M.D., and Patrick McCartney. The expansion of the board coincides with the successful completion of an initial pilot clinical study.
By Jean P. Hubble, M.D. The diagnosis is usually quite obvious – rhythmic shaking of the hands. Despite the fact that essential tremor (ET) is common and easily recognized, there are many aspects about the clinical presentation which are poorly understood. Virtually all individuals with ET have tremor of the hands. The next most frequently […]
Clinical trials can be confusing. Amber Trzeciak, with Cadent Therapeutics, explains how they work and why they are important for the development of new drugs and treatments for medical conditions like essential tremor.